title: Bisphenol A in chronic kidney disease.
abstract: The estrogenic endocrine-disrupting substance bisphenol A (BPA) is extensively used as a starting material for a variety of consumer plastic products including dialyzer materials. The present study was performed to explore plasma BPA levels in patients with impaired renal function and to investigate if dialyzers differing in elutable BPA influence plasma levels in patients on maintenance hemodialysis. In vitro BPA was eluted from high-flux polyethersulfone (PUREMA H, referred as PUR-H), high-flux polysulfone (referred as HF-PSu), and low-flux polysulfone (referred as LF-PSu) dialyzers by recirculation with water for 180 min. In a cross-sectional clinical study, plasma BPA levels of outpatients with different stages of chronic kidney disease (CKD) from four different centers were determined. Furthermore, in a prospective, randomized, and crossover setting, 18 maintenance dialysis patients were subjected successively to 4 weeks of thrice-weekly hemodialysis with each LF-PSu, HF-PSu, and PUR-H. In addition, the fractions of protein-bound and free BPA were determined in a subset of dialysis patients. The mass of BPA eluted from the blood compartments in vitro under aqueous conditions varied for the three dialyzers being very low for PUR-H (6.2 ± 2.5 ng; P < 0.001), intermediate for HF-PSu (48.1 ± 7.7 ng), and highest for LF-PSu (140.8 ± 38.7 ng; P < 0.01). In 152 prevalent patients with CKD enrolled in the cross-sectional trial, plasma BPA started to rise after stage 3. Maintenance hemodialysis patients had more than six times higher BPA concentrations than patients with CKD stage 5 not yet on dialysis (10.0 ± 6.6 vs. 1.6 ± 1.8 ng/mL; P < 0.001). The BPA concentrations highly and inversely correlated with renal function. In the randomized controlled study, the plasma BPA concentrations were highly elevated compared with healthy controls (range 9.1 ± 4.5-12.0 ± 6.0 ng/mL vs. ≤0.2 ± 0.1 ng/mL; P < 0.001), but no change of the plasma levels was observed during hemodialysis with any of the three dialyzers in the course of a single treatment and over a period of 4 weeks. The protein-bound fraction of plasma BPA in the dialysis patients was 74 ± 5%. Renal function and, most likely, the total quantity of ingested BPA are essential parameters affecting plasma BPA concentrations. Dialyzers are one additional source of BPA, but differences in the elutable BPA content are not associated with a significant effect on BPA plasma levels in Western European maintenance dialysis patients. Due to high protein binding, the removal of BPA by hemodialysis is limited.
authors.affiliation: Department of Medicine, Division of Nephrology, University of Würzburg, Oberdürrbacher Strasse 6, Würzburg, Germany. krieter_d@medizin.uni-wuerzburg.de
authors.forename: Detlef H
authors.initials: DH
authors.lastname: Krieter
authors.forename: Bernard
authors.initials: B
authors.lastname: Canaud
authors.forename: Horst-Dieter
authors.initials: HD
authors.lastname: Lemke
authors.forename: Annie
authors.initials: A
authors.lastname: Rodriguez
authors.forename: Andreas
authors.initials: A
authors.lastname: Morgenroth
authors.forename: Kai
authors.initials: K
authors.lastname: von Appen
authors.forename: Gerd-Peter
authors.initials: GP
authors.lastname: Dragoun
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000097:blood*; D018592:Cross-Over Studies; D003430:Cross-Sectional Studies; D052244:Endocrine Disruptors / Q000097:blood*; D004867:Equipment Design; D005060:Europe; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010636:Phenols / Q000097:blood*; D011108:Polymers / Q000737:chemistry*; D011446:Prospective Studies; D011485:Protein Binding; D006435:Renal Dialysis / Q000295:instrumentation*; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D013450:Sulfones / Q000737:chemistry*; D013997:Time Factors; D000098826:Bisphenol A Compounds
chemical_list: D001559:Benzhydryl Compounds; D052244:Endocrine Disruptors; D008567:Membranes, Artificial; D010636:Phenols; D011108:Polymers; D013450:Sulfones; C017662:polysulfone P 1700; C022840:polyether sulfone; C006780:bisphenol A; D000098826:Bisphenol A Compounds